Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;26(3):267-278.
doi: 10.1007/s11916-022-01025-x. Epub 2022 Feb 7.

Neuromodulation for Chronic Daily Headache

Affiliations
Review

Neuromodulation for Chronic Daily Headache

Gianluca Coppola et al. Curr Pain Headache Rep. 2022 Mar.

Abstract

Purpose of review: We reviewed the literature that explored the use of central and peripheral neuromodulation techniques for chronic daily headache (CDH) treatment.

Recent findings: Although the more invasive deep brain stimulation (DBS) is effective in chronic cluster headache (CCH), it should be reserved for extremely difficult-to-treat patients. Percutaneous occipital nerve stimulation has shown similar efficacy to DBS and is less risky in both CCH and chronic migraine (CM). Non-invasive transcutaneous vagus nerve stimulation is a promising add-on treatment for CCH but not for CM. Transcutaneous external trigeminal nerve stimulation may be effective in treating CM; however, it has not yet been tested for cluster headache. Transcranial magnetic and electric stimulations have promising preventive effects against CM and CCH. Although the precise mode of action of non-invasive neuromodulation techniques remains largely unknown and there is a paucity of controlled trials, they should be preferred to more invasive techniques for treating CDH.

Keywords: Deep brain stimulation; Direct current stimulation; Occipital nerve; Sphenopalatine ganglia; Transcranial magnetic stimulation; Trigeminal nerve; Vagus nerve.

PubMed Disclaimer

Conflict of interest statement

G. C., F. C., G. S., C. A., E. C. C. D. L., and M. S. declare no conflict of interest related to the topic of the present manuscript. D. M. received research and travel grants from ElectroCore. She contributed to the study with the supraorbital device Cefaly Technology without any compensation. She took place to several advisory boards organised by Medtronic without any compensation. She kindly received support for training from Theranica Bio-Electronics Ltd without any compensation.

Figures

Fig. 1
Fig. 1
Schematic representation of the sites of possible neuromodulatory intervention in chronic daily headaches. A Transcranial magnetic stimulation on the scalp, B direct current stimulation on the scalp, C transcutaneous stimulation of the supraorbital branch of the trigeminal nerve, D transcutaneous stimulation of the vagus nerve at the neck, E percutaneous stimulation of the great occipital nerve, and F deep brain stimulation of the posteroinferior hypothalamus or ventral tegmentum (Created with BioRender.com)

References

    1. Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–235. - PubMed
    1. Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E, et al. Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia. 2017;37:965–978. - PubMed
    1. Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470–485. - PMC - PubMed
    1. Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn) 2015;21:973–989. - PMC - PubMed
    1. Turner DP, Golding AN, Houle TT. Using a graphical risk tool to examine willingness to take migraine prophylactic medications. Pain. 2016;157:2226–2234. - PMC - PubMed

MeSH terms